Press

Archived News Reports   |  Archived Press Releases   |  Back to Current News

 

Archived News Reports

2018

Alnylam, Founded by Westphal, Sharp, Schimmel, Receives Approval for First RNAi Therapy
Wall Street Journal: August 10, 2018
Read More

Bicycle Therapeutics Ahead of the Curve in Fight Against Cancer
Business Weekly: July 13, 2018
Read More

2017

Michelle Dipp Wants to Make A Difference
G20 Ventures: June 6, 2017
Read More

2016

Microbiome CNS Upstart Launches with $19.15M Series A
FierceBiotech: November 30, 2016
Read More

A New Way to Prevent Muscle Cramps
Wall Street Journal: July 11, 2016
Read More

2015

Meet the World's First Baby Born With an Assist from Stem Cells
Time: May 7, 2015
Read More

2014

Flex Pharma Developing Treatments for Muscle Cramps
Boston Globe: October 25, 2014
Read More

To Fight Cramps, Christoph Westphal Taps Boston All-Stars for $40M
Xconomy: September 9, 2014
Read More

Christoph Westphal Globe Article on Boston’s Prominence in Medicine, Music isn’t an Accident
Boston Globe: August 9, 2014
Read More

Executive Profile: Arthur Tzianabos of OvaScience
Boston Business Journal: August 29, 2014
Read More

Christoph Westphal Globe Article on Boston, Hub of the Pharma Universe
Boston Globe: July 14, 2014
Read More

Christoph Westphal Globe Article on the Biotech Industry and a Cure for Hepatitis C
Boston Globe: June 9, 2014
Read More

Longwood Portfolio Company Verastem in Bloomberg’s New Cancer Drug Targets Article
Bloomberg: May 1, 2014
Read More

Christoph Westphal Globe Article on Boston's Blooming Biotech Ecosystem
Boston Globe: February 23, 2014
Read More

2013

Verastem Launches Ovarian Cancer Trial
Boston Business Journal: February 5, 2013
Read More

2010

Scientists Target Tumors’ Most Resilient Cells
By: Ron Winslow | Wall Street Journal: December 21, 2010
Read More

Focus Turns to Cancer Stem Cells
By: Karen Weintraub | The Boston Globe: December 1, 2010
Read More

 

Archived Press Releases

2018

Millendo Announces Initiation of Phase 2b Clinical Trial of Nevanimibe in Patients with Classic CAH
Read More

IlluminOss Medical Receives Clearance to Expand Clinical Indications in the US
Read More

KalVista Pharmaceuticals Announces the Closing of its Public Offering of Common Stock and Full Exercise of the Underwriters’ Over-allotment Option to Purchase Additional Shares
Read More

ArcherDX Names Former Foundation Medicine Executive Steven Kafka, Ph.D. to its Board of Directors
Read More

Twentyeight-Seven Therapeutics Launches with a $65 Million Series A Funding
Read More

Verastem Oncology Announces Investigator Sponsored Study on Duvelisib in Combination with Venetoclax
Read More

Colorescience Product Wins Second O-Ward
Read More

Amgen Co-Founder and NAS Member Marvin H. Caruthers, PhD, Joins Board of ArcherDX
Read More

Renovia Completes $42.3 Million Series B Financing
Read More

Colorescience Partners with HydraFacial
Read More

GRAIL Announces Appointment of Hal Barron and Hans Bishop to its Board of Directors
Read More

OvaScience and Millendo Therapeutics Announce Merger to Create Leading Rare Endocrine Disease Company
Read More

KalVista Pharmaceuticals advancing pipeline; $14.6M raised
Read More

Colorescience Receives Patent for Formulation of Even Up® Clinical Pigment Perfector
Read More

Recros Medica Announces New Patent Issued by USPTO
Read More

Parkinson’s Institute and Clinical Center and Axial Biotherapeutics Announce Collaboration to Target Gastrointestinal Metabolites that May Contribute to Parkinson’s Disease
Read More

GRAIL Announces Data on Detection of Early-Stage Lung Cancers
Read More

Bicycle Therapeutics Announces Formation of Scientific Advisory Board
Read More

Bicycle Therapeutics Announces Clinical Milestone & Expands Collaboration with Thrombogenics
Read More

Bicycle Therapeutics Expands Strategic Partnership with AstraZeneca
Read More

GRAIL Announces $300 Million Raised in Oversubscribed Series C Financing
Read More

Axial Reports Findings of Elevated 4-EPS in Children with Autism Spectrum Disorder
Read More

Colorescience Launching in the UK
Read More

GRAIL Announces Data from Prototype Blood Tests for Early Cancer Detection
Read More

Washington University, ArcherDX partner for MRD in pediatric AML sequencing study
Read More

FDA Accepts New Drug Application for Verastem's Duvelisib and Grants Priority Review
Read More

Flex Pharma Reports Positive RCT Phase 2 MS Study
Read More

ArcherDX and Ambry Genetics to provide immune repertoire and CAR-T- related sequencing services
Read More

ArcherDX Closes $35 Million Series A Financing
Read More

Bicycle Therapeutics and Cancer Research UK Announce Initiation of First Clinical Study of a Bicyclic Peptide (Bicycle®)
Read More

Colorescience Introduces Total Eye 3-in-1 Renewal Therapy SPF 35
Read More

IlluminOss Medical Granted FDA Marketing Clearance for the IlluminOss® Bone Stabilization System
Read More

KalVista Pharmaceuticals Commences Two Clinical Trials
Read More

2017

GRAIL Announces Appointment of Jennifer Cook as Chief Executive Officer
Read More

Pulmocide Commences a Human RSV Challenge Study with PC786
Read More

Enrollment Completed in Flex Pharma’s Phase 2 Exploratory Spasticity Study in MS
Read More

Pulmocide's PC945 in Phase 1 Study
Read More

Channel Medsystems® Earns CE Mark Approval for the Cerene® Cryotherapy Device
Read More

Pulmocide Raises $30 Million in Series B Financing
Read More

2016

Axial Biotherapeutics Announces the Groundbreaking Discovery of a Biological Link Between the Gut Microbiome and Parkinson's Disease Published in Cell
Read More

Axial Biotherapeutics Launches to Treat Patients with CNS Disorders by Harnessing the Gut Microbiome
Read More

Channel Medsystems Secures IDE Approval and Treats First Women in the CLARITY Pivotal Study
Read More

Millendo Licenses Phase 2 Polycystic Ovary Syndrome (PCOS) Drug Candidate from AstraZeneca and Secures Series B Financing of $62 Million to Advance Pipeline of Endocrine Disorder Therapies
Read More

2015

OvaScience's AUGMENT Fertility Treatment Available in Japan
Read More

Channel Medsystems Secures $22 Million Series C Financing Led by Third Point Ventures
Read More

OvaScience Expands AUGMENTSM Fertility Treatment Offering through IVI Group, the Largest IVF Clinic Network in the World
Read More

KalVista Pharmaceuticals Raises $33 Million to Advance Development of Novel Plasma Kallikrein Inhibitors in Diabetic Macular Edema and Hereditary Angioedema
Kalvista News

OvaScience Ranks #11 on MIT Technology Review's 50 Smartest Companies of 2015
Read More

OvaScience CEO Michelle Dipp Elected as Young Global Leader by World Economic Forum
Ovascience News

Verastem Receives Orphan Drug Designation from FDA for VS-5584 in Mesothelioma
Read More

Flex Pharma Prices Upsized IPO with $84M Offering
Read More

Verastem Announces Closing of $54 Million Public Offering of Common Stock and Exercise in Full of Underwriters' Option to Purchase Additional Shares
Read More

Verastem Doses First Patient in Phase 1 Clinical Trial Evaluating VS-5584 in Combination with VS-6063 in Mesothelioma
Read More

Verastem Receives Orphan Medicinal Product Designation from the European Commission for VS-5584 in Mesothelioma
Read More

OvaScience Announces Closing of $132 Million Public Offering of Common Stock including Exercise of Underwriters' Option to Purchase Additional Shares
Read More

2014

Flex Pharma Presents Results From Three Human Clinical Studies
Read More

Verastem Presents New Data on Mesothelioma Programs at the 12th International Mesothelioma Interest Group Meeting
Read More

OvaScience CEO Talks Apple, Facebook and the $9 Billion Fertility Market
Read More

OvaScience CEO Michelle Dipp Elected to Board of Directors of Beth Israel Deaconess Medical Center
More Ovascience News

OvaScience CEO Michelle Dipp Named Outstanding Young Leader
More Ovascience News

Colorescience Announces Successful Completion of $15 Million Series B Preferred Stock Offering
Read More

Flex Pharma Raises $40 Million — Top Tier Syndicate Supports Novel Treatments for Neuromuscular Disorders
Read More

Flex Pharma Forms Distinguished Scientific Advisory Board
Read More

European Medicines Agency Recommends First-in-Class Medicine for Treatment of Duchenne Muscular Dystrophy
Read More

OvaScience Co-Founder David Sinclair, Ph.D., Selected by TIME as one of the 100 Most Influential People in The World
More Ovascience News

OvaScience Prices $50 Million Public Offering of Common Stock
More Ovascience News

Calithera Biosciences Initiates Three Phase 1 Trials with First-in-Class Glutaminase Inhibitor CB-839 in Patients with Advanced Solid and Hematological Cancers
More Calithera News

PTC’s Joint Program In Spinal Muscular Atrophy Enters First Stage Of Clinical Development
Read More

2013

Verastem Announces Addition to the NASDAQ Biotechnology Index
Read More

OvaScience and Intrexon Collaborate to Accelerate Development of OvaScience's OvaTureSM Technology for Infertility Treatments
More Ovascience News

Astellas Pharma Inc. Announces R&D Collaboration and Exclusive Right to Acquire an Option to Purchase Longwood Portfolio Company Mitokyne in Q2 2013 Financial Results Call
Read More

Calithera Biosciences Secures $35 Million in Series D Financing
Read More

Astellas and Mitokyne to Pursue Mitochondria-Related Disease Therapies
Read More